Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459608) titled 'Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma' on March 5.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Henan Cancer Hospital
Condition:
Indolent Lymphoma
WM
MZL
CLL / SLL
Intervention:
Drug: Lisaftoclax
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: March 10, 2026
Target Sample Size: 75
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07459608
Published by ...